AIM ImmunoTech (AIM) Interest & Investment Income (2013 - 2022)
AIM ImmunoTech's (AIM) quarterly Interest & Investment Income came in at $79000.0 in Q2 2022, up 54.9% YoY from $51000.0 in Q2 2021, and up 75.56% on a QoQ basis from $45000.0 in Q1 2022.
AIM ImmunoTech (AIM) Interest & Investment Income (2013 - 2022) Analysis & Trends
AIM ImmunoTech (AIM) has 9 years of Interest & Investment Income data on file, last reported at $79000.0 in Q2 2022.
- Quarterly Interest & Investment Income rose 54.9% year-over-year to $79000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $155000.0 (down 18.42% YoY) and the FY2018 annual result came in at $9000.0, up 152.94% from the prior year.
- Interest & Investment Income rose to $79000.0 in Q2 2022, from $45000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $79000.0 in Q2 2022 to a low of -$20000.0 in Q3 2021.
- A 5-year average of $28769.2 and a median of $29000.0 in 2018 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2020 — Interest & Investment Income soared 3550.0% — and 2021, when it plunged 128.99%.
- Tracing AIM's Interest & Investment Income over 5 years: stood at $29000.0 in 2018, then sank by 106.9% to -$2000.0 in 2019, then soared by 3550.0% to $69000.0 in 2020, then sank by 128.99% to -$20000.0 in 2021, then jumped by 495.0% to $79000.0 in 2022.
- The last three Interest & Investment Income figures came in at $79000.0 (Q2 2022), $45000.0 (Q1 2022), and -$20000.0 (Q3 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 79,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Sep 30, 2021 | -20,000.00 |
| Jun 30, 2021 | 51,000.00 |
| Mar 31, 2021 | 72,000.00 |
| Sep 30, 2020 | 69,000.00 |
| Sep 30, 2019 | -2,000.00 |
| Jun 30, 2019 | -6,000.00 |
| Mar 31, 2019 | 3,000.00 |
| Dec 31, 2018 | 29,000.00 |
| Sep 30, 2018 | -1,000.00 |
| Jun 30, 2018 | 51,000.00 |
| Mar 31, 2018 | 4,000.00 |
| Dec 31, 2017 | -11,000.00 |
| Sep 30, 2017 | 13,000.00 |
| Jun 30, 2017 | 21,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Dec 31, 2016 | 1,000.00 |
| Sep 30, 2016 | 40,000.00 |
| Jun 30, 2016 | 55,000.00 |